Biodesix, Inc. (NASDAQ:BDSX) just released its latest quarterly results and things are looking bullish. Revenues and losses per share were both better than expected, with revenues of US$27m leading estimates by 3.2%. Statutory losses were smaller than the analystsexpected, coming in at US$0.71 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

After the latest results, the six analysts covering Biodesix are now predicting revenues of US$111.5m in 2026. If met, this would reflect a decent 8.3% improvement in revenue compared to the last 12 months. Losses are expected to hold steady at around US$2.66. Before this earnings announcement, the analysts had been modelling revenues of US$111.0m and losses of US$2.96 per share in 2026. While the revenue estimates were largely unchanged, sentiment seems to have improved, with the analysts upgrading their numbers and making a favorable reduction in losses per share in particular.

These new estimates led to the consensus price target rising 5.9% to US$32.67, with lower forecast losses suggesting things could be looking up for Biodesix. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Biodesix at US$40.00 per share, while the most bearish prices it at US$27.00. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Biodesix'shistorical trends, as the 17% annualised revenue growth to the end of 2026 is roughly in line with the 15% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 5.0% annually. So it's pretty clear that Biodesix is forecast to grow substantially faster than its industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

With that in mind, we wouldn't be too quick to come to a conclusion on Biodesix. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Biodesix going out to 2028, and you can see them free on our platform here..

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.